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Skeletal muscle formation in vertebrates is derived from the paraxial mesoderm, which develops into
myogenic precursor cells and ﬁnally differentiates into mature myoﬁbers. This myogenic program involves
temporal-spatial molecular events performed by transcription regulators (such as members of the Pax, MRFs
and Six families) and signaling pathways (such as Wnts, BMP and Shh signaling). Epigenetic regulation,
including histone post-translational modiﬁcations is crucial for controlling gene expression through re-
cruitment of various chromatin-modifying enzymes that alter chromatin dynamics during myogenesis. The
chromatin modifying enzymes are also recruited at regions of muscle gene regulation, coordinating tran-
scription regulators to inﬂuence gene expression. In particular, the reversible methylation status of histone
N-terminal tails provides the important regulatory mechanisms in either activation or repression of muscle
genes. In this report, we review the recent literatures to deduce mechanisms underlying the epigenetic
regulation of gene expression with a focus on histone methylation modiﬁcation during embryo myogenesis
and adult muscle regeneration. Recent results from different histone methylation/demethylation mod-
iﬁcations have increased our understanding about the highly intricate layers of epigenetic regulations in-
volved in myogenesis and cross-talk of histone enzymes with the muscle-speciﬁc transcriptional machinery.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Embryo myogenesis or adult muscle regeneration is the pro-
gramming of a population of muscle progenitors, embryonic or
fetal myoblasts and satellite cells (SCs) into committing to the
myogenic lineages and of myoblasts into differentiating into ma-
ture myoﬁbers. The formation of skeletal muscles involves both
genetic and epigenetic changes that culminate in alterations in
gene expression [1]. Chromatin-modifying enzymes and re-
modeling complexes orchestrate the pattern of gene expression
and reprogram the myogenic lineage toward terminal differ-
entiation [1,2]. The transcriptional regulation of muscle speciﬁca-
tion has been well characterized, and the role of histone acetyla-
tion modiﬁcation in control of muscle-speciﬁc gene expression has
been studied extensively, however, less is known about the role of
histone methylation modiﬁcation in this process [3]. Here, we
review the potential roles of histone modiﬁcations during myo-
genesis with a focus on H3 lysine 27 tri-methylation (H3K27me3),
H3 lysine 4 tri-methylation (H3K4me3) and H3 lysine 9 di/tri-
methylation (H3K9me2/3) markers at myogenic gene regulatory
regions in myoblasts and satellite cells.2. Myogenesis: gene regulatory networks and transcriptional
mechanisms
2.1. Development of embryo myogenesis
Skeletal muscle is initiated in the somite (epithelial spheres along
the anterior–posterior axis of the embryo) which derives from
paraxial mesoderm adjacent to the neural tube and notochord [2,4,5].atic representation of developmental myogenesis. It shows that the somi
nd myoblasts differentiate into myotubes. During this process, the actio
nd gene regulatory networks are performed by myogenic transcriptionaThe newly formed dorsal somites rapidly differentiate into dermo-
myotomes, which are the source of muscle precursor cells. Cells from
the dorsomedial part of the somites adjacent to the neural tubes
migrate under the dermomyotomes to form the myotomes [6]. The
myotomes are committed and differentiate into myoblasts, and ﬁnal
maturation of myotubes fuse into myoﬁbers (Fig. 1). The epaxial
(dorso-medial) part of the dermomyotomes and myotomes generate
the back muscles while the hypaxial (ventro-lateral) somites gen-
erate the rest of the trunk and limb muscles [7–9].
2.2. Genetic regulatory networks in myogenesis
2.2.1. Regulation of transcription regulators in myogenesis
The paired-homeobox family of transcription factors Pax3 and
Pax7 are important upstream regulators of the myogenic process
in the embryo myogenesis. In Splotch mice, because of mutation of
Pax3, cells fail to develop the hypaxial domain of the somite and
thus lack limb musculature and other muscle masses in the body.
However, epaxial-derived muscles are less affected [6,10–12]. In
the chick embryo, Pax3:Pax7-positive cells are maintained as
proliferating cells and do not express myogenic regulatory factors
or muscle proteins. However, they can give rise to skeletal muscle
cells leading to subsequent skeletal muscle differentiation and
producing muscle satellite cells [13]. Pax3:Pax7 double mutants die
at early fetal stages. In the absence of both Pax3 and Pax7 proteins,
muscle progenitor cells do not activate the myogenic determina-
tion genes to enter the myogenic program [14].
The myogenic regulatory factors (MRFs) of MyoD, Myf5, myo-
genin and Mrf4 genes have highly conserved basic helix-loop-helix
domain (bHLH) structure and are expressed in the skeletal muscletes give rise to muscle progenitor cells, progenitor cells determinate and proliferate
n of both positive and negative signals control the spatio-temporal expression of
l factors.
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creases gradually while MRF family gene expression increases
signiﬁcantly [17]. The high expression of Myf5 gene forms the
primitive muscle structure containing committed muscle cells
[15,18]. Subsequently, MyoD gene is activated after the onset of
Myf5 expression in the dermomyotome [4,19]. Two of these factors
are muscle determination genes. They are the major factors that
activate the myogenic program in muscle and non-muscle cells
[20]. In contrast to MyoD and Myf5, myogenin is a key gene for
activating the muscle differentiation program. The number of
skeletal muscle ﬁbers are reduced in mice carrying mutations in
myogenin [21,22]. The role of Mrf4 is more complicated in myo-
genesis. Mrf4 closely linked with Myf5 gene in mice is activated in
myotomes following the Myf5 expression, and its expression is
reinitiated in differentiating muscle cells stage. Overexpression of
Mrf4 can compensate for the muscle ﬁbers in myogenin double
mutations embryo [23,24].
The myocyte enhancer factor 2 family alone has no myogenic
activity but they assist the MRFs through transcriptional co-
operation to mediate expression of muscle-speciﬁc genes [25,26].
MyoD family of MRFs have MEF2 binding sites, so MEF2 could
provide a positive feedback loop and cooperative interactions be-
tween many MRF proteins [27]. The other families of transcription
factors for myogenesis are the Six family of homeobox proteins
Six1 (the sine oculis-related homeobox 1) and Six4 and their
transcriptional cofactors eyes-absent homologs Eya1 and Eya2. Six
proteins associate with the Eya1 and Eya2, generating a regulatory
cascade that directs dermomyotomal progenitor cells toward the
myogenic lineage. Hence, they are critical in the migration of hy-
paxial myogenic precursor cells from the somite to the limb and
serve as upstream regulators of Pax3, MyoD and myogenin during
somitogenesis [28–30].
2.2.2. Regulation of extracellular signals in myogenesis
During embryogenesis, the adjacent structures in embryo re-
lease both positive (Wnt, Sonic hedgehog (Shh) and noggin) and
negative (BMP4 and Notch) signals that control the spatial and
temporal expression pattern (Fig. 1). All of these signals regulate
the amount of myogenic regulatory factors for balancing between
proliferation and differentiation status during muscle develop-
ment [2,15].
Wnt signaling is involved in forming the dermomyotome and
myotome [15,31]. Wnt1 and Wnt3 are produced by the dorsal
neural tube, and Wnt4, Wnt6 and Wnt7a are produced by the
surface ectoderm [32]. The expression of the Pax3 and Myf5 is
increased byWnt1 and Wnt3 [33], while the expression of MyoD is
reduced by Wnt6 and Wnt7a [34]. Moreover, Wnt signaling acti-
vates the program of myogenesis through the TCF/β-catenin
pathway [8]. β-catenin acts as a Wnts receptor and is present in
the myotome depending on Wnt1 or Wnt3a. β-catenin interacts
with Shh and is up-regulated in the dorsal somite prior to MyoD
activation.
Shh signaling regulates myogenesis mechanism through the
down-regulation of Pax3/7 and up-regulation of Myf5/MyoD ex-
pression, leading to myogenic cells to withdraw from proliferation
and start differentiation [38–40]. Whereas Shh signaling is con-
trolled by Wnt signaling through the regulation of Gli2 and Gli3
[35].
BMP4 (bone morphogenic protein 4) can up-regulate Pax3 ex-
pression in the embryonic trunk [36]. Overexpression of BMP4 in
the somite can inhibit MyoD expression, resulting in the inhibition
of myotome formation [37]. Overexpression of BMP2b increases
expression of Pax3 and the number of Pax7-positive myogenic
precursor cells and delays muscle differentiation via decreasing
MyoD expression in the zebraﬁsh embryo [38]. As BMP4's an-
tagonist, noggin lies downstream of the Shh and Wnt signalingpathways and physically interacts with it and counteracts the ef-
fects of BMP4 on myotome formation [39,40].
The activity of Notch signaling inﬂuences cell differentiation,
proliferation, and apoptotic programs [41]. Stimulation of Notch
signaling in Pax3-positive myogenic progenitor cells inhibits
muscle differentiation and causes a reduction in myogenic cells
that migrate into the limbs [42]. MyoD cooperated with the DNA
binding protein RBP-J and the transcriptional repressor Hes1
(hairy and Enhancer of split) can suppress Notch signaling activity
[43]. Hes1 also effectively inhibits MyoD, inducing myogenic
conversion of C3H10T1/2 cells into muscle cells [44]. Two-hybrid
assays indicate that constitutively active Notch is able to block
MEF2C DNA binding ability [45].
The p38 MAPK (p38 mitogen-activated protein kinase) signal-
ing is an intracellular signaling pathway that activates myogenic
cell lines to affect the muscle transcription program. In mice,
(1) p38 is rapidly activated during myocyte differentiation. Con-
versely, inhibition of p38 activity prevents the differentiation in
myogenic cell lines and human primary myocytes, (2) over-
expression of p38 stimulates the transcriptional activity of MyoD
and in embryonic ﬁbroblasts of p38 double mutant mice, the ef-
ﬁciency of MyoD-dependent myogenic conversion is reduced, and
(3) p38 signaling activates MEF2C transcription factor through
selective phosphorylation of MEF2C on Thr293 residue in differ-
entiating myocytes [46–48].
2.3. Adult muscle regeneration: common mechanisms and mediators
Adult muscle regeneration or de novo myogenesis in verte-
brates depends on the injured tissue recruiting an undifferentiated
myogenic progenitor cells or muscle stem cells to the site of injury.
In adult skeletal muscle, this function is provided by the satellite
cells [4,15,49,50]. Responding to injury, quiescent satellite cells are
activated and then proliferate as myoblast cells and differentiate to
form new muscle ﬁbers or returned to quiescence to maintain the
stem cell pool (self-renewal).
2.3.1. Regulation of transcription regulators in adult muscle
regeneration
Similarly, in embryo myogenesis, Pax7 as a satellite cell marker
is expressed in quiescent satellite cells in muscles from throughout
the body [4,14,19,49,51–53] and Pax7 is co-expressed with MyoD
in their proliferating myoblast progeny [54]. Pax3 is expressed in
satellite cell in muscles from approximately 50% of forelimb
muscles and most ventral trunk muscles [49]. Constitutive ex-
pression of Pax3 or Pax7 in satellite cells results in an increased
proliferative rate and prevents differentiation [54]. Interestingly, in
Pax7mutant cells, the cell number progressively decreases in both
Pax3-expressing and Pax3-non-expressing muscles. It has been
shown that Pax7 cannot be compensated by Pax3 during the
postnatal development of skeletal muscles [49]. In addition, recent
studies analyzing the role of Pax7 in adult satellite cells have de-
monstrated that temporary deletion of Pax7 in adult satellite cells
results in normal muscle regeneration after injury, indicating that
Pax7 is not required for de novo myogenesis in the adult [55], but
long-term Pax7 abrogation leads to loss of adult satellite cells,
resulting in impaired muscle regeneration after injury [56,57].
Myf5 gene is already expressed in quiescent satellite cells.
MyoD gene is expressed in the activated satellite cells and, along
with down-regulation of Pax7 expression, subsequently differ-
entiates with the expression of myogenin gene [49,50,58–60].
However, overexpressing Pax7 in myoblasts represses MyoD ex-
pression and inhibits myogenesis. Ectopic expression of Pax7 can
efﬁciently block the MyoD-dependent conversion of mesenchymal
stem cells (10T1/2 cells) to the muscle lineage [61]. These studies
suggest that satellite cells are heterogeneous population cells.
Fig. 2. A schematic representation of adult muscle regeneration. Upon muscle injury, quiescent satellite cells are activated and divided asymmetrically, generating a self-
renewing cell and a committed progenitor which begins to express Myf5. Next, activated satellite cells express MyoD and down-regulate Pax7. Then activated satellite cells
will differentiate and fuse to form new myoﬁbers during adult muscle regeneration.
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to committed myogenic progenitors which later undergoes differ-
entiation. The molecular mechanisms may involve in a reciprocal
inhibition between Pax7 and the muscle regulatory factors (Fig. 2).
2.3.2. Regulation of extracellular signaling in adult muscle
regeneration
Studies with adult muscle regeneration indicate that Wnt sig-
naling induces CD45þstem cells puriﬁed from regenerating mus-
cle to form determined myoblasts but fails to induce CD45þstem
cells puriﬁed from uninjured muscle to form myogenic cells. Re-
generating muscles with rejection of Wnt antagonists sFRP2/3
inhibits CD45þstem cells proliferation and myogenic speciﬁcation.
β-catenin, as a key downstream transcriptional co-activator of Wnt
signaling, is strongly up-regulated in satellite cells and during
muscle regeneration. Other studies indicate that activation of the
Wnt/β-catenin signaling pathway causes changes in the structure
of chromatin at the MyoD and Myf5 promoters, leading to in-
creases in the expression of Myf5 and MyoD in satellite cells and in
the number of proliferative Pax7þ/Myf5þ and Pax7þ/MyoDþ cells
in skeletal muscle. All of these ﬁndings suggest that Wnt signaling
plays a critical role in the regulation of satellite cells in adult
muscle regeneration [62–65].
Notch-1 is expressed in satellite cells, and its activity is es-
sential for maintaining the expression of Pax7. Attenuation of
Notch signaling by increasing expression of inhibitor Numb leads
to the commitment of satellite cells to the myoblasts fate [66,67].3. The epigenetic modiﬁcations in myogenesis and adult
muscle regeneration
3.1. Epigenetic code
The concept of “Epigenetics” was ﬁrst introduced by Conrad
Waddington in 1942. After decades of research, epigenetics has
been found to involve DNA methylation, histone modiﬁcation,
chromatin remodeling, and non-coding RNAs (ncRNAs) in mam-
malian animals [68]. For nucleosomes, the basic unit of chromatin,
the amino residues on histone tails (histone amino termini or
histone N-termini) are subject to diverse arrays of covalent post
translational modiﬁcations, including acetylation, methylation,
phosphorylation, and ubiquitination. Distinct histone modiﬁca-
tions generate synergistic or antagonistic interaction for chroma-
tin-associated proteins, which in turn determine dynamic transi-
tions between transcriptionally active or silent states of chromatin
[69,70]. Histone modiﬁcations inﬂuence chromatin packaging and
are read by adaptor molecules, chromatin modifying enzymes,transcription factors and transcriptional repressors, and thus
contribute to the regulation of transcription. Epigenetic histone
modiﬁcations have been best characterized for histones H3 and H4
[71]. Histone methylation occurs on arginine and lysine amino
acids residues. Mono-, di- or tri-methylation has been discovered
on histone H3 and H4 [68]. H3K4me3 has been associated with
euchromatin and facilitates active transcription by recruiting the
RNA polymerase II complex at gene promoter/enhancer regions
[72]. In contrast, H3K27me3 is mutually exclusive with H3K4me3,
which is generally considered a repression marker for transcrip-
tion [73]. H3K9me2 or H3K9me3 is linked to silencing of gene
expression at euchromatin and heterochromatin [74].
3.2. Epigenetic modiﬁcations in embryo development
3.2.1. Epigenetic modiﬁcations in embryonic stem (ES) cells
Embryo development proceeds from a cascade of gene activa-
tion and repression. Differentially expressed embryonic genes are
regulated by various patterns of histone modiﬁcations on un-
methylated DNA, which create a developmentally permissive
chromatin state and confer a speciﬁc chromatin conﬁguration on
gene regulatory and coding regions [71,75]. The analysis of histone
modiﬁcations in ES cells has generated genome-wide maps of
H3K27me3 and H3K4me3 [76]. ChIP assays for zebraﬁsh embryos
show that all embryonic gene promoters have severe deacetyla-
tion on H3K9 and H4 relative to H3K4me3. Deacetylation is ac-
companied by enrichment in H3K9me3 and H3K27me3, suggesting
that embryonic genes are associated with repressing histone
modiﬁcations in ﬁbroblasts [75]. ChIP-chip experiments form de-
velopmental transition from late fetus to lamb during late ovine
skeletal muscle development reveal that H3K27me3 modiﬁcation
is associated with genes, transcription start sites (TSS) and CpG
islands and with transcriptional silencing. Most modiﬁed genes
have no changes during the muscle transition, indicating that
H3K27me3 does not have a large role in late muscle maturation
[77]. These ﬁndings suggest that H3K27me3 represses develop-
mental genes at initial embryonic stages.
Recent data from studies in ES cells show that the function of
H3K4me3 in ES cells is poising the expression of embryonic genes
that allows for the proper activation of lineage regulators upon
differentiation, but its mechanism remains unclear. How H3K4me3
and H3K27me3 markers are established in ES cells is still unclear.
The existing evidence shows that some developmental regulatory
genes are already marked by H3K4me3 and H3K27me3 in sperm
[76,78].
A prevalent model in stem cell biology suggests that the loss of
pluripotency entails global increase in heterochromatin and co-
incident shutdown of lineage-unrelated genes [79]. H3K9me2
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and occupies large parts (450%) of the genome in ES cells. Ana-
lysis of the H3K9me2 in ES cells shows that active regions are
mutually exclusive with H3K9me2, and the majority of H3K4me2
regions are mutually exclusive with H3K9me2 [79,80]. Moreover,
G9a has been implicated in embryonic development, based on the
embryonic lethality of G9a knockout mice [81].
3.2.2. Bivalency of H3K4 and H3K27 methylation
Bivalent domains were ﬁrst identiﬁed at the TSS of key reg-
ulators of lineage determination in cultured ES cells [65]. ChIP-
chip studies in human and mouse ES cells show that develop-
mental genes are maintained in a bivalent status. These bivalent
promoters are maintained in a repressive chromatin state through
H3K27me3, however, the presence of an active chromatin mod-
iﬁcation H3K4me3 suggests that these genes are poised for rapid
induction [82,83].
In ES cells, Polycomb group (PcG) proteins predominantly
suppress H3K4-methylated CpG island promoters. Polycomb re-
pressive complex 2 (PRC2) and polycomb repressive complex 1
(PRC1) seem to cooperate to counteract H3K4 methylation. PRC2
contributes to silencing by recruiting H3K4 histone demethyl-
transferases, thereby regulating the homeostasis of the bivalent
state. Furthermore, PRC2 facilitates PRC1 targeting by providing
the H3K27me3 binding site [83]. Similarly, the studies of Orford
and colleagues show that H3K4me2þ/me3- or H3K4me2þ/me3þ
CpG island promoters are repressed at the progenitor stage by the
presence of H3K27me3, but non-CpG island tissue-speciﬁc genes
are amenable to marking by H3K4me2 “only” [83,84]. During
myoblasts differentiation, modiﬁcations of H3-K4 by Set7 and H3-
K9 by Suv39h1 are mutually exclusive at the promoters/enhancers
of myogenic differentiation genes [85].
Pax3 is the only myogenic transcription factor with bivalent
domains in quiescent satellite cells, which correlates well with the
low expression levels of Pax3 in satellite cells of adult mice. In
contrast, Pax7 is only marked by H3K4me3 at its TSS. On the other
hand, myogenin is not marked by either H3K4me3 or H3K27me3 in
quiescent satellite cells, but shows signiﬁcant enrichment of the
H3K4me3 mark at its TSS upon activation [86].
3.3. Histone methylation modiﬁcations in myogenesis
The transition from proliferation into differentiation of muscle
cells is accompanied by a number of chromatin-associatedFig. 3. Regulation of histone methyltransferases in muscle differentiation. In proliferatio
histone methytransferases represses expression of muscle differentiation genes and m
myoblasts and quiescent satellite cells are activated, the cooperation of myogenic genes a
myogenic triggering signaling cascades (e.g. p38 signaling). The H3K4 tri-methylation
entiated muscle cells.complexes with histone modiﬁcations through dynamic changes
in chromatin to balance activation or repression at regulation of
muscle genes transcription. Histone methylation modiﬁcations as
“on/off” switches play an important role in lineage commitment
and differentiation (Fig. 3). Generally, transient and long-term
gene silencing are performed by tri-methyl histone H3 on lysine
9 and 27, and gene activation is regulated by tri-methylation of
H3K4.
3.3.1. H3K27 methylation modiﬁcation
Tri-methyl lysine modiﬁcations on histones are the most stable
epigenetic marks and control chromatin-mediated regulation of
gene expression [87,88]. H3K27me3 is known to regulate muscle
differentiation through silencing muscle-speciﬁc genes and is
widely distributed throughout the genome in both myoblasts and
myotubes, including promoters, gene bodies, and intergenic re-
gions [89]. While PcG proteins have histone lysine methyl-
transferase activity, PRC2 catalyzes tri-methylation of histone H3
lysine 27 that is associated with transcriptional silencing [90–92].
The global mapping analysis reveals that the PcG proteins bind a
large number of tissue-speciﬁc differentiation genes such as
myogenin and CKM, which are speciﬁcally induced in muscle dif-
ferentiation [92]. The Ezh2 protein is one component of PRC2 [93].
Ezh2 is expressed in the myotome compartment of mouse somite
and in proliferating satellite cells and is down-regulated in term-
inally differentiated muscle cells. This coincides with activation of
muscle gene expression in differentiation of myoblasts. In un-
differentiated myoblasts, endogenous Ezh2 is associated with the
transcriptional regulator YY1 and histone deacetylase HDAC1. And
the complex will occupy genomic regions of silent muscle-speciﬁc
genes [91].
3.3.2. H3K4 methylation modiﬁcation
Trithorax (TrxG) group proteins are known for antagonizing
polycomb group proteins repressing. These two group of proteins
establish the transcription patterns that maintain the repressed or
active transcription states of developmentally important genes
[94]. TrxG proteins with a SET domain catalyze tri-methylation of
H3 lysine 4 [94]. H3K4me3, as an active marker, is almost ex-
clusively found in promoter regions of actively transcribed genes
[87,88]. Chromatin immunoprecipitation experiments ﬁnd that
the promoter region of myogenin gene becomes enriched in
H3K4me3 during C2C12 cell differentiation. As Ash2L protein is a
component of H3K4 methyltransferase complexes and isn of myoblasts and quiescent satellite cells, the cooperation of myogenic genes and
aintains H3K27 or H3K9 methylation on muscle-speciﬁc gene promoters. Once
nd histone methytransferases are released by histone demethyltransferases or pro-
status exists at the chromatin region of muscle-speciﬁc gene promoters in differ-
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dicates that MEF2 (MEF2D and MEF2C) is associated with Ash2L
and MLL complexes (including MLL2, Set1 and MLL3) which is
recruited to the myogenin promoter in differentiated C2C12 cells
and the nucleosomes containing H3K4me3 during C2C12 cell dif-
ferentiation. And this process needs phosphorylation of MEF2D by
p38-α via p38 signaling pathway [95–97].
Mixed lineage leukemia 5 (MLL5) is an H3K4 methyltransferase
encoding a SET and PHD domain protein homologous to Droso-
phila Trithorax and yeast SET3, but appears to lack intrinsic HMT
activity. In quiescent myoblasts, MLL5 regulates both the cell cycle
and differentiation via a hierarchy of chromatin and transcrip-
tional regulators. Knocking down MLL5 delays entry of quiescent
myoblasts into S phase, but hastens S-phase completion by indu-
cing the expression of cyclin E and cyclin A (CycA). Meanwhile,
CycA mRNA is induced throughout G0/G1, with activation of the
cell cycle regulated element (CCRE) in the CycA promoter. Com-
paring with normal cells, defective differentiation in MLL5
knockdown myoblasts correlates with reduced expression of Pax7
throughout the cell cycle, suppressed expression of Myf5 in G0,
with delayed G1 induction, altered function of MyoD, and in-
efﬁcient activation of myogenin [98].
Set7, the H3K4 speciﬁc methyltransferase, catalyzes H3K4 me-
thylation in vitro and in vivo and potentiates transcription activa-
tion. Set7 contains a SET domain, but lacks the pre- and post-SET
domains [99]. Studies show that the expression of Set7 is dyna-
mically increased during normal skeletal muscle differentiation.
Knockdown of Set7 by siRNA represses the expression of MyoD,
myogenin and MyHC and reduces the number of myotubes.
Moreover, Set7 physically interacts with MyoD and Set7 associa-
tion and the H3K4 monomethylation status on the regulatory re-
gions of myogenic differentiation genes substantially increased
during C2C12 cells differentiation. All of these ﬁndings suggest
that Set7 has a role in skeletal muscle development and is required
for the terminal differentiation of skeletal muscle myoblasts [85].
3.3.3. H3K9 methylation modiﬁcation
Suv39h1/KMT1A is a H3K9 speciﬁc methyltransferase catalyz-
ing di- or tri-methylation of histone H3 lysine 9 [100,101], that is
associated with Heterochromatin protein 1 (HP1) in gene silencing
[102,103]. Studies reveal that Suv39h1 has multi-roles in regulat-
ing muscle genes transcription during muscle cell differentiation.
Mal et al. demonstrate that Suv39h1 interacts with MyoD and
represses MyoD-dependent muscle gene expression. This repres-
sion requires Suv39h1 association with MyoD and sustains me-
thylation of H3K9 on myogenin promoter [104]. Ait-Si-Ali et al.
demonstrate that Suv39h1 depleted myoblasts have a poor capa-
city to fuse into myotubes and are unable to express early and late
muscle differentiation markers, such as myogenin, MCK and MyHC
[105].
G9a is a member of SET domain containing Suv39 family [106]
and it mainly catalyzes mono- or di-methylation of histone H3
lysine 9 in euchromatin [81,107]. G9a is also involved in catalyzing
histone H3 lysine 9 tri-methylation [108] and histone H3 lysine 27
methylation [106]. Recently, G9a is reported to have a dynamical
expression mode during skeletal muscle cells differentiation. G9a
can inhibit skeletal muscle cells differentiation in a methyl-
transferase activity-dependent manner by mediating H3K9me2
around MyoD target gene promoters. In addition, G9a catalyzes
MyoD methylation at K104 site in a methyltransferase activity-
dependent manner to constrain its transcriptional activity [107].
Sharp-1, a DNA-binding transcription and basic helix-loop-he-
lix transcription factor, is a potent repressor of skeletal muscle
differentiation via negatively affecting MyoD function by compe-
tition for binding to E-box sites, formation of inactive hetero-
dimers, and inhibition of its transcriptional activity. Sharp-1 isexpressed widely in a number of cell types, including developing
skeletal muscles. Current evidence demonstrates that G9a associ-
ates with and enhances Sharp-1-mediated transcriptional repres-
sion and meanwhile overexpression of Sharp-1 correlates with
increased H3K9me2 on the myogenin promoter and enhanced
MyoD-G9a association and MyoD methylation in C2C12 cells [109].
3.4. Histone demethylation modiﬁcations in myogenesis
3.4.1. H3K9 demethylation modiﬁcation
Histone demethyltransferases regulates gene expression by
removing histone methyl group marks [110]. LSD1 (Lysine Speciﬁc
Demethylase 1), a nuclear homolog of amine oxidases, is a lysine
speciﬁc demethyltransferase which is responsible for removing
methyl group from mono-, di-methylation of H3K4 and H3K9
[111–113]. Therefore, LSD1 can repress H3K4 transcription activa-
tion and activate H3K9 transcription repression [114]. Current
studies have proven that expression of LSD1 is increasing during
myogenic cells differentiation. LSD1 is directly associated with
MyoD and MEF2 on their target promoters to activate myogenic
genes in vivo. Abrogation of LSD1 can cause myoblasts without
differentiation ability. In short, it suggests that catalytic activity of
LSD1 is vital for skeletal muscle cells differentiation [115].
Another histone lysine demethyltransferase (KDM) JHDM2A, a
jumonji (or JmjC) domain containing protein that speciﬁcally re-
moves methyl group from H3K9 [116,117]. JHDM2A mediates the
demethylation of mono- and di-methyl H3K9 in vitro and in vivo
[117]. A new isoform of JMJD2A, named DN-JMJD2A, lacks the
N-terminal demethyltransferase domain whose expression is up-
regulated during muscle cells differentiation [3]. DNA microarray
analysis indicates that the expression of muscle-speciﬁc genes as
myogenin and CKM are strongly decreased by knockdown DN-
JMJD2A. ChIP analysis indicates that DN-JMJD2A is recruited to
myogenin promoter and DN-JMJD2A can promote the demethyla-
tion of H3K9me2 at myogenin promoter [3]. Moreover, DN-JMJD2A
promotes MyoD induced-myogenic conversion of NIH3T3 cells
into muscle cells [3].
Another JmjC domain containing demethyltransferases (Jmjd),
Jmjd2C, one of Jmjd2 family members, demethylates histone
H3K9me2 and H3K9me3. It has been reported that Jmjd2C in-
creases MyoD transcriptional activity to facilitate skeletal muscle
differentiation by increasing MyoD stability through inhibiting
G9a-dependent MyoD degradation [118].
3.4.2. H3K27demethylation modiﬁcation
The UTX (ubiquitously transcribed tetratricopeptide repeat, X
chromosome) protein, belongs to a subfamily of JmjC domain-
containing proteins. As mammalian H3K27 speciﬁc demethyl-
transferases, the UTX removes di- and tri-methyl group
fromH3K27me2/3 [119–121]. UTX is enriched around the tran-
scription starting sites of many HOX genes in primary human ﬁ-
broblasts, and UTX is present in the MLL2/3/4 containing histone
H3K4 methyltransferase complexes altering histone methylation
dynamics. These ﬁndings suggest that UTX is essential for H3K27
methylation regulation and is also important for the stringent
regulation of transcription during cellular differentiation [119–
121]. In differentiating myoblasts, UTX is recruited to the tran-
scriptional regulatory region of both the myogenin and CKM genes
with removal of the repressive H3K27me3 mark at both genes.
Knockdown of UTX in C2C12 cells prevents the formation of
multinucleated, MyHC-positive myotubes [122]. The recent ﬁnd-
ings demonstrate that UTX with an important role in mediating
demethylation of H3K27me3 at muscle-speciﬁc genes during
myogenesis. In addition, histone chaperoneSpt6 is reported to
promote UTX chromatin enrichment and reduce H3K27me3 level
at myogenin regulation regions [123].
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In proliferating satellite cells, histones associated with the
promoters of genes speciﬁcally involved in muscle differentiation
are hypo-acetylated and contain H3K9me2, H3K9me3 and
H3K27me3 residues [65]. Pax7 is a key mark in satellite cells and
has predominant function during the postnatal development of
skeletal muscles. Studies on protein–protein interactions provide a
post-translational modiﬁcation mechanism for regulating Pax7
and Pax7 target genes Myf5 and MyoD function in satellite cells.
3.5.1. H3K27 methylation modiﬁcation
H3K27 methyltransferases play important roles in the epige-
netic regulation of stem cell quiescence. Ezh2 is expressed in
quiescent satellite cells and required for homeostasis of the adult
satellite cell pool [124]. When proliferating myoblasts receive
differentiation signals, phosphorylation of the enhancer of Ezh2
recruits the Trithorax group/Ash2L complex through p38-phos-
phorylated MEF2D and induces transition from a transcriptionally
permissive H3K4me3 mark to a repressive H3K27me3 mark on the
Pax7 promoter to down-regulate its expression. Myogenic genes
that are highly expressed in proliferating or differentiated cells,
such as MyoD and myogenin, are also marked by the repressive
H3K27me3 mark [97,125,126]. While in activated satellite cells, the
level of H3K27me3 increases signiﬁcantly across the genome,
whereas theH3K4me3 mark is retained [65,127].
Mice with satellite cell-speciﬁc inactivation of Ezh2 have re-
duced muscle mass, a decreased number of satellite cells and ex-
hibit defective regeneration after injury. These differences have
been attributed to a failure of the proliferative progenitor popu-
lation to expand (Ezh2 maintains a key phase of muscle satellite
cell expansion but does not regulate terminal differentiation.) and
to impair maintenance and/or return to quiescence (self-renewal)
after injury [124].
3.5.2. H3K4 methylation modiﬁcation
Yeast two-hybrid screening, tandem afﬁnity puriﬁcation (TAP)
and mass spectrometry experiments indicate that Pax7 is asso-
ciated with the Wdr5–Ash2L–MLL2 histone methyltransferases
complex which directs methylation of H3K4 at the Myf5 promoter,
resulting in H3K4 tri-methylation of surrounding chromatin
[96,128,129]. The comparative microarray analysis, siRNA, ﬂuor-
escence-activated cell sorting (FACS) and ChIP conﬁrm thatMyf5 is
directly regulated by Pax7 in C2C12 cells which are derived from
satellite cells [128]. Currently protein–protein interaction experi-
ments indicate that Pax7 is a substrate of CARM1, and CARM1
could speciﬁcally methylate multiple arginine in the N-terminus of
Pax7. Methylated Pax7 directly binds to C-terminal cleavage forms
of MLL1/2 and recruits Ash2L:MLL1/2:Wdr5:Rbbp5 histone H3K4
methyltransferase complex to regulatory enhancers and the
proximal promoter of Myf5 [95,130]. Together, these experiments
provide important epigenetic mechanisms that Pax7 stimulates
transcriptional activation of MyoD family of target genes to reg-
ulate entry into the myogenic developmental program by inducing
chromatin methylation modiﬁcation.
3.5.3. H3K9 methylation modiﬁcation
The p38 signaling is a trigger in satellite cells during muscle
regeneration. p38-γ is highly expressed in skeletal muscles. During
adult myogenesis, p38-γ phosphorylates MyoD on Ser199 and
Ser200, which results in enhanced occupancy of MyoD on the
promoter of myogenin together with markedly decreased tran-
scriptional activity. This repression is associated with extensive
methylation of histone H3K9 together with recruitment of the
Suv39h1/KMT1A methyltransferase to the myogenin promoter.
Notably, a MyoD S199A/S200A mutant exhibits markedly reducedbinding to Suv39h1/KMT1A. Therefore, p38-γ signaling directly
induces the assembly of a repressive MyoD transcriptional com-
plex [131].
3.6. Other methylation modiﬁcations and histone chaperones in
myogenesis
CARM1, referred to as PRMT4 (protein arginine N methyl-
transferase 4), is deﬁned as a type of the S-adenosyl-L-methio-
nine-dependent methyltransferases, which catalyzes the methy-
lation of arginine residues on speciﬁc proteins [132]. The expres-
sion of CARM1 is detected in somites during embryogenesis and in
the nuclei of muscle cells. Protein-protein interaction assay sys-
tems demonstrate that CARM1 directly interacts with the
C-terminal region of MEF2C in vivo and CARM1 cooperates with
the steroid receptor co-activator (SRC) cofactor GRIP-1 to stimulate
MEF2C. Inhibition of CARM1 dramatically reduces the myogenin
and MEF2 protein level and morphological differentiation of pro-
liferating myoblasts into multinucleated myotubes. CARM1/PRMT4
is necessary for skeletal muscle differentiation [133].
Spt6 (Suppressor of Ty 6), as a transcription elongation factor
and histone chaperone, interacts with RNA polymerase II (Pol II) to
reassemble nucleosomes during Pol II elongation [134] and inter-
acts with histones and primarily with histone H3 in controlling
chromatin structure, respectively [135–137]. Spt6 is considered
critical for somite formation in zebraﬁsh embryogenesis. Genetic
and biochemical experiments demonstrate that Spt6 is essential
for the transcriptional response to activation of the Notch path-
way: her1 and her7, two of Notch pathway key target genes for
somite formation, are suppressed by disruption of Spt6 function in
panSBU2 (Zebraﬁsh Spt6 mutants) embryos [138]. Spt6 associated
with Pol II is recruited at chromatin regions of muscle-speciﬁc
genes and is required for appropriate muscle-speciﬁc genes ex-
pression in myoblasts (e.g., MyoD and des) and differentiated
myotubes (e.g., myogenin, MyH3, MyoD, des and Mylpf) [123].
Histone chaperone HIRA (HIR histone cell cycle regulation de-
fective homolog A) is a human homolog of the S. cerevisiae HIR1
and HIR2 (histone regulatory) [139–141]. HIR1 and HIR2 proteins
act as co-repressors to assist a repressor that repress histone gene
transcription in S. cerevisiae [142]. HIRA is classiﬁed as DNA re-
plication-independent chaperone and speciﬁcally chaperones at
H3.3 in mammalian variants [139]. It has been conﬁrmed that
HIRA interacts with MEF2 and stimulates MEF2 target genes
transcription during muscle differentiation [143].
3.7. Methylation modiﬁcation at myogenic regulators
As a myogenic regulator, MyoD can regulate transcription at
gene promoters. Moreover, MyoD can also bind enhancers and
mediates the recruitment of several chromatin-modifying en-
zymes, such as Set7, which catalyzes histone H3K4me1 to active
enhancers [65,144,145], or Suv39h1, which catalyzes histone
H3K9me2/3 to inhibit MyoD transcriptional activity [104]. In ad-
dition, MyoD can also be as a substrate that catalyzed by chro-
matin-modifying enzyme. Unlike Suv39h1, G9a not only mediates
H3K9me2 but also directly methylates MyoD at K104 to inhibit its
transcriptional activity [107]. Similarly, MEF2 activity is also
regulated by posttranslational modiﬁcations, such as methylation.
Recently studies ﬁnd that MEF2D is methylated and demethylated
by G9a and LSD1 at its K267, respectively, which effects the dy-
namic regulation of MEF2D transcriptional activity and the ex-
pression of its target genes during skeletal muscle differentiation
[146].
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Chromatin modiﬁers mediate dynamic modiﬁcations of histone
tails that are vital to reprogramming cells toward terminal differ-
entiation. Genetic and epigenetic mechanisms ensure that com-
plex developmental programs are correctly executed [83].
In this report, we review the recent literature to deduce me-
chanisms underlying a complex interplay between myogenic
regulatory factors and histone methylation modiﬁcations and re-
veal the reciprocal regulation between histone methyltransferases
and demethyltransferases in the control of gene expression during
skeletal muscle myogenesis and regeneration (Fig. 3). We also
elucidate that histone chaperones play critical roles in controlling
of muscle gene regulatory programs in this review. In addition, we
ﬁnd that histone methyltransferases not only mediate dynamic
modiﬁcations of histone tails for inﬂuencing myogenic gene ex-
pression during skeletal myogenesis but also catalyze myogenic
regulatory factors methylation at lysine site in controlling of gene
transcription activity. To date, little is known about the role of
histone methylation modiﬁcations in adult muscle regeneration.
However, a similar regulatory mechanism from myogenesis might
regulate the availability and composition of chromatin modifying-
complexes that promote muscle gene transcription in adult muscle
regeneration. Likewise, we predict that histone methylation-
modifying enzymes mediate dynamic modiﬁcations of histone
tails that are vital to programming myogenic precursors (satellite
cells) toward terminal differentiation in adult muscle regeneration.
The networks established by myogenic regulatory factors and
chromatin-associated enzymatic complexes will provide an im-
portant paradigm to understand the epigenetic regulation of ske-
letal muscle development and regeneration, and help to decipher
the molecular pathways that control the transition from skeletal
muscle progenitors to ﬁbers—a current challenge in regenerative
medicine [147].
Moreover, the current approach of ChIP assays is suitable for
chromatin from small cell numbers, but limited by the number cell
samples. Thus, establishing chromatin state maps across genome
(genome-wide changes in the epigenetic landscape) is an open
avenue for investigation. While most of the ﬁndings outlined here
are based on cell culture studies, in vivo models or animal ex-
periments need to be explored. Moreover, chromatin plasticity and
epigenetic changes during muscle differentiation have yet to be
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